Literature DB >> 17333044

[Survival with distant metastatic disease in head and neck cancer. A retrospective analysis].

B Dietl1, J Marienhagen, C Schaefer, F Pohl, T Murthum, O Kölbl.   

Abstract

QUESTIONS: The objective of this retrospective analysis was to investigate parameters with a potential impact on survival in a collective of 114 patients with distant metastatic disease after head and neck cancer. PATIENTS AND METHODS: The primary endpoint was the survival with distant metastatic disease, the secondary endpoint was overall survival. Primary therapy, local recurrence, second neoplasms, palliative chemotherapy (CHT) and radiotherapy (RT), as well as Karnofsky performance status (KPS) at the time of diagnosis of the metastases were analyzed as potential impact parameters using the log-rank test with subsequent Cox regression analysis.
RESULTS: Palliative CHT (P=0.0020) and KPS (P=0.0011) had a significant positive impact on the median survival probability with metastases (8.2 months) using the log-rank test, KPS at the time of diagnosis of metastases remained as an independent prognostic parameter in the Cox regression (P=0.0013). Primary therapy, local tumor control and KPS had a significant positive influence on the median overall survival probability (18.5 months) univariately (P=0.0139, P=0.0106, P= 0.0096) and multivariately (P=0.0123, and P=0.0063, P=0.0197, respectively).
CONCLUSIONS: KPS at the time of diagnosis of metastases is an independent prognostic parameter for both endpoints. Lacking evidence for life prolongation, palliative therapies should therefore first and foremost focus on the stabilization of the KPS.

Entities:  

Mesh:

Year:  2007        PMID: 17333044     DOI: 10.1007/s00106-006-1522-4

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  42 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

Review 2.  Role of taxoids in head and neck cancer.

Authors:  D Schrijvers; J B Vermorken
Journal:  Oncologist       Date:  2000

3.  [Transoral resection of locally advanced squamous cell carcinoma of the side wall of the oropharynx: multimodal treatment concepts in transition].

Authors:  C Simon; P K Plinkert
Journal:  HNO       Date:  2006-08       Impact factor: 1.284

Review 4.  Palliative radiation therapy.

Authors:  Andre Konski; Steven Feigenberg; Edward Chow
Journal:  Semin Oncol       Date:  2005-04       Impact factor: 4.929

5.  [Quality of life in patients with oropharyngeal carcinoma. Gender influences the subjective evaluation].

Authors:  I Baumann; M Seibolt; I M Zalaman; K Dietz; P K Plinkert; M M Maassen
Journal:  HNO       Date:  2006-05       Impact factor: 1.284

6.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Authors:  A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

7.  Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients.

Authors:  Joern Wulf; Ulrich Haedinger; Ulrich Oppitz; Wibke Thiele; Gerd Mueller; Michael Flentje
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-09-01       Impact factor: 7.038

Review 8.  [Palliative chemotherapy of head and neck cancer: present status and future development].

Authors:  B Hennemann
Journal:  Laryngorhinootologie       Date:  2006-03       Impact factor: 1.057

9.  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

Authors:  C Jacobs; G Lyman; E Velez-García; K S Sridhar; W Knight; H Hochster; L T Goodnough; J E Mortimer; L H Einhorn; L Schacter
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

10.  Single-dose radiotherapy (6 Gy): palliation in painful bone metastases.

Authors:  J M Uppelschoten; S L Wanders; J M de Jong
Journal:  Radiother Oncol       Date:  1995-09       Impact factor: 6.280

View more
  2 in total

1.  Survival of patients with head and neck cancer. Impact of physical status and comorbidities.

Authors:  F Sadat; A Wienke; J Dunst; T Kuhnt
Journal:  Strahlenther Onkol       Date:  2011-12-23       Impact factor: 3.621

2.  The crucial role of SEMA3F in suppressing the progression of oral squamous cell carcinoma.

Authors:  Yi Liu; Ronghua Li; Kai Yin; Gang Ren; Yongdong Zhang
Journal:  Cell Mol Biol Lett       Date:  2017-12-28       Impact factor: 5.787

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.